Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML)

In addition to spliceosome gene mutations, oncogene expression and drug resistance in AML might influence exon expression. We performed exon-array analysis and exon-specific PCR (ESPCR) to identify specific landscapes of exon expression that are associated with DEK and WT1 oncogene expression and the resistance of AML cells to AraC, doxorubicin or azacitidine. Data were obtained for these five conditions through exon-array analysis of 17 cell lines and 24 patient samples and were extended through qESPCR of samples from 152 additional AML cases. More than 70% of AEUs identified by exon-array were technically validated through ESPCR. In vitro, 1,130 to 5,868 exon events distinguished the 5 conditions from their respective controls while in vivo 6,560 and 9,378 events distinguished chemosensitive and chemoresistant AML, respectively, from normal bone marrow. Whatever the cause of this effect, 30 to 80% of mis-spliced mRNAs involved genes unmodified at the whole transcriptional level. These AEUs unmasked new functional pathways that are distinct from those generated by transcriptional deregulation. These results also identified new putative pathways that could help increase the understanding of the effects mediated by DEK or WT1, which may allow the targeting of these pathways to prevent resistance of AML cells to chemotherapeutic agents.

[1]  H. Dombret,et al.  Azacitidine for the treatment of relapsed and refractory AML in older patients. , 2015, Leukemia research.

[2]  Eduardo Eyras,et al.  Detection of recurrent alternative splicing switches in tumor samples reveals novel signatures of cancer , 2015, Nucleic acids research.

[3]  D. Auboeuf,et al.  HTLV-1-infected CD4+ T-cells display alternative exon usages that culminate in adult T-cell leukemia , 2014, Retrovirology.

[4]  Ulrich Mansmann,et al.  Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis. , 2014, Blood.

[5]  M. Thénoz,et al.  How mRNA is misspliced in acute myelogenous leukemia (AML)? , 2014, Oncotarget.

[6]  P. Rohrlich,et al.  Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines , 2014, Oncotarget.

[7]  E. Solary,et al.  The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases , 2014, Leukemia.

[8]  D. Auboeuf,et al.  A recently evolved class of alternative 3′-terminal exons involved in cell cycle regulation by topoisomerase inhibitors , 2014, Nature Communications.

[9]  J. Chen,et al.  Alternative splicing in cancer: implications for biology and therapy , 2014, Oncogene.

[10]  P. Pilarski,et al.  A Genome-Wide Aberrant RNA Splicing in Patients with Acute Myeloid Leukemia Identifies Novel Potential Disease Markers and Therapeutic Targets , 2013, Clinical Cancer Research.

[11]  L. Scott,et al.  Acquired mutations that affect pre-mRNA splicing in hematologic malignancies and solid tumors. , 2013, Journal of the National Cancer Institute.

[12]  J. Maciejewski,et al.  Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms. , 2013, Blood.

[13]  I. Palumbo,et al.  WT1 regulates murine hematopoiesis via maintenance of VEGF isoform ratio. , 2013, Blood.

[14]  M. Rozman,et al.  Age, JAK2V617F and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis , 2013, Leukemia.

[15]  J. Valcárcel,et al.  The spliceosome as a target of novel antitumour drugs , 2012, Nature Reviews Drug Discovery.

[16]  J. Stuchly,et al.  Real-time PCR quantification of major Wilms’ tumor gene 1 (WT1) isoforms in acute myeloid leukemia, their characteristic expression patterns and possible functional consequences , 2012, Leukemia.

[17]  J. Rowley,et al.  Two isoforms of HOXA9 function differently but work synergistically in human MLL-rearranged leukemia. , 2012, Blood cells, molecules & diseases.

[18]  Daniel Birnbaum,et al.  Myeloid malignancies: mutations, models and management , 2012, BMC Cancer.

[19]  James T. Webber,et al.  C/EBPα and DEK coordinately regulate myeloid differentiation. , 2012, Blood.

[20]  J. Valcárcel,et al.  Alternative Splicing and Cancer , 2012, Journal of nucleic acids.

[21]  J. Maciejewski,et al.  Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders , 2012, Leukemia.

[22]  H. Dombret,et al.  Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study , 2012, The Lancet.

[23]  Sigrun M. Hjelle,et al.  Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia , 2012, Oncogene.

[24]  P. Spitali,et al.  Splice Modulating Therapies for Human Disease , 2012, Cell.

[25]  A. Krainer,et al.  RNA therapeutics: beyond RNA interference and antisense oligonucleotides , 2012, Nature Reviews Drug Discovery.

[26]  Verena I Gaidzik,et al.  TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. Ladomery,et al.  WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. , 2011, Cancer cell.

[28]  G. Roboz.  Novel approaches to the treatment of acute myeloid leukemia. , 2011, Hematology. American Society of Hematology. Education Program.

[29]  Tom Misteli,et al.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.

[30]  E. Jacquet,et al.  ATP Binding Cassette transporters associated with chemoresistance: transcriptional profiling in extreme cohorts and their prognostic impact in a cohort of 281 acute myeloid leukemia patients , 2011, Haematologica.

[31]  Verena I Gaidzik,et al.  RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Y. Hayashi,et al.  Prognostic significance of the BAALC isoform pattern and CEBPA mutations in pediatric acute myeloid leukemia with normal karyotype: a study by the Japanese Childhood AML Cooperative Study Group , 2010, International journal of hematology.

[33]  K. Moysich,et al.  Genetic polymorphisms of ATP-binding cassette (ABC) proteins, overall survival and drug toxicity in patients with Acute Myeloid Leukemia. , 2010, International journal of molecular epidemiology and genetics.

[34]  R. Porcher,et al.  Quantification of VEGF Isoforms and VEGFR Transcripts by qRT-PCR and Their Significance in Acute Myeloid Leukemia , 2009 .

[35]  B. Morris,et al.  WT1 interacts with the splicing protein RBM4 and regulates its ability to modulate alternative splicing in vivo. , 2006, Experimental cell research.

[36]  F. de Longueville,et al.  ABCA3 as a Possible Cause of Drug Resistance in Childhood Acute Myeloid Leukemia , 2006, Clinical Cancer Research.

[37]  J. Valcárcel,et al.  Intron Removal Requires Proofreading of U2AF/3' Splice Site Recognition by DEK , 2006, Science.

[38]  Ruoping Tang,et al.  MRP3, BCRP, and P-Glycoprotein Activities are Prognostic Factors in Adult Acute Myeloid Leukemia , 2005, Clinical Cancer Research.

[39]  O. Legrand,et al.  Breast Cancer Resistance Protein and P-Glycoprotein in 149 Adult Acute Myeloid Leukemias , 2004, Clinical Cancer Research.

[40]  M. Pfaffl,et al.  Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper – Excel-based tool using pair-wise correlations , 2004, Biotechnology Letters.

[41]  山口 博樹.  The study for loss of bcl-xs expression as a prognostic factor in acute myeloid leukemia , 2004 .

[42]  G. Schuurhuis,et al.  Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia. , 2003, Haematologica.

[43]  C. Galmarini,et al.  In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia , 2002, British journal of haematology.

[44]  E. Vellenga,et al.  Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia , 2000, Leukemia.

[45]  M. Grever,et al.  Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. , 1999, Blood.

[46]  A. Lamond,et al.  WT1 interacts with the splicing factor U2AF65 in an isoform-dependent manner and can be incorporated into spliceosomes. , 1998, Genes & development.

[47]  K. Miyagawa,et al.  Does the Wilms’ tumour suppressor gene, WT1, play roles in both splicing and transcription? , 1995, Journal of Cell Science.

[48]  T. Murayama,et al.  Establishment of a leukaemic cell line from a patient with acquisition of chromosomal abnormalities during disease progression in myelodysplastic syndrome , 1993, British journal of haematology.

[49]  M. Fornerod,et al.  The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA , 1992, Molecular and cellular biology.

[50]  T. Tsuruo,et al.  Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. , 1992, Blood.